Abstract:

To date, clinical data on long-term clinical outcomes, including 6-month mortality and relapse in talaromycosis (Tm) patients and impacts of ART and secondary antifungal prophylaxis are still lacking. We conducted a secondary data analysis from 6-month prospective observation of patients with culture-confirmed talaromycosis who participated in the Itraconazole versus Amphotericin B for HIV-associated Talaromycosis (IVAP) trial. The primary outcome was 6-month Tm mortality, while the secondary outcome was relapse. Multivariable Cox proportional hazard models were used to identify predictors of outcomes of interest. The median patient age was 34 years (IQR:30 – 38). The median pre-ART CD4 counts at baseline were 10 (IQR: 5-21) cells/µL. The cumulative 76/435 (17.4%) patients died, and Tm relapse was observed in 18/435 (4.1%) patients. The multivariable analyses showed that strong independent predictors of 6-month Tm mortality included ineffective ART (either absence of ART or ART failure) (HR = 6.26, 95% CI: 3.95 – 9.92, P < 0.001), and TB co-infection (HR =1.98, 95% CI: 1.23 – 3.17; P < 0.01). Induction antifungal treatment with itraconazole versus amphotericin B deoxycholate was significantly associated with Tm death in the univariable model, however, it became insignificant in the multivariable model. In addition, the significant risk factors for Tm relapse were ineffective ART, induction antifungal treatment with itraconazole than intravenous amphotericin B, and shorter duration of itraconazole secondary prophylaxis after completing induction therapy in-hospital (all with significant P-values). Antiretroviral therapy, antifungal treatment and tuberculosis co-infection were main predictors for 6-month Tm fatality as well as relapse.

References:

[1] Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110-3.

[2] Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbio Rev. 2006; 19:95-110.

[3] Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011; 52:945–952.

[4] Larsson M, Nguyen LH, Wertheim HF, Dao TT, Taylor W, Horby P, et al. Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam. AIDS Res Ther. 2012; 9:24.

[5] Son VT, Khue PM, Strobel M. Penicilliosis and AIDS in Hai Phong, Vietnam: Evolution and predictive factors of death. Med Mal Infect. 2014; 44:495-501.

[6] Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013; 13:464.

[7] Hu Y, Zhang J, Li X, Yang Y, Zhang Y, Ma J, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013; 175:57-67.

[8] Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med. 2017; 376:2329-2340.

[9] Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. 1998; 339:1739-43.

[10] Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS. 2007; 21:365-7.

[11] Thanh NT, Vinh LD, Liem NT, Shikuma C, Day JN, Thwaites G, Le T. Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated with Talaromyces marneffei infection. Med Mycol Case Rep. 2016; 19:33-37.

[12] The R Project for Statistical Computing, version 4.2.2, 2023. Available at https://www.r-project.org/. Accessed and cited on 8 August 2023.

[13] Jiang J, Meng S, Huang S, Ruan Y, Lu X, Li JZ, et al. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infect. 2019; 25:233-241.

[14] Thanh NT, Thu NTM, Ly VT, Guy T, Le T. Paradoxical Immune Reconstitution Inflammatory Syndrome associated with Talaromyces marneffei Infection among ART-Naïve Patients. The Asia Pacific AIDS & Co-infections Conference 2019 (APACC) June 27-29, 2019, Hong Kong.

[15] Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Health Res Policy. 2019; 4:32.

[16] Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N, et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare
facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017; 72: 3141-3148.

[17] Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016; 71:2918-27.

[18] Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010; 10 :155-66.

[19] Thanh NT, Dat NT. Prevalence of HIV-associated Co-infections and Clinical Characteristics among HIV/AIDS Outpatients in the Context of Dolutegravir Roll-out Program in Vietnam. Texila International Journal of Public Health 2022.doi:10.21522/TIJPH.2013.10.02.Art021.

[20] World Health Organization. Transition to new antiretroviral drugs in HIV programmes: clinical and programmatic considerations. Geneva: 2017. [Internet]. [Accessed and cited on 9 August 2023]. Available from: http://apps.who.int/iris/bitstream/10665/255887/1/WHO-HIV-2017.23-eng.pdf?ua=1.

[21] Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. Afr Health Sci. 2016; 16:588-95.